Want to see HK:1093 full AI Analyst Report?
Top Page
CSPC Pharmaceutical Group
(1093)
Select Model
Select Model
Rating:80Outperform
Price Target:
HK$9.00
â–Ľ(-5.46% Downside)
Action:Reiterated
Date:08/21/26
The score is driven primarily by strong financial quality—especially the very low leverage balance sheet and resilient profitability—supported by reasonable valuation (P/E ~12.56 and ~3.05% yield). Technicals are constructive with the price above key moving averages and neutral-to-positive momentum, though the overall score is moderated by recent revenue softness and margin compression versus earlier years.
Positive Factors
Very low leverage
Extremely low leverage gives CSPC substantial financial flexibility and reduces exposure to interest costs and refinancing pressure. This conservative funding structure should help the company continue investing in pharmaceutical development and commercialization while providing resilience if operating conditions weaken.
Negative Factors
Soft revenue growth
Recent revenue performance shows that CSPC’s top-line expansion has weakened after declines in 2023 and 2024. The return to only low-single-digit growth in 2025 may constrain operating leverage and indicates that portfolio adoption and commercial momentum are not accelerating consistently.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Extremely low leverage gives CSPC substantial financial flexibility and reduces exposure to interest costs and refinancing pressure. This conservative funding structure should help the company continue investing in pharmaceutical development and commercialization while providing resilience if operating conditions weaken.
Read all positive factors
CSPC Pharmaceutical Group (1093) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$90.26B
Dividend Yield4.2%
Average Volume (3M)65.34M
Price to Earnings (P/E)10.3
Beta (1Y)0.66
Revenue Growth25.21%
EPS Growth103.93%
CountryHK
Employees18,626
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.65
Shares Outstanding11,522,452,000
10 Day Avg. Volume66,627,088
30 Day Avg. Volume65,336,021
Financial Highlights & Ratios
PEG Ratio-1.94
Price to Book (P/B)2.90
Price to Sales (P/S)3.80
P/FCF Ratio24.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$13.73Price Target Upside44.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)0.77
Revenue Forecast (FY)HK$32.94B
CSPC Pharmaceutical Group Business Overview & Revenue Model
Company Description
CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is dedicated to the development, production, and distribution of pharmaceutical goods. Its operations span the globe, with a significant presence in the People's Republic o...
How the Company Makes Money
CSPC Pharmaceutical Group makes money primarily by selling pharmaceutical products and related services through its operating subsidiaries. Its core revenue model is product-based: (1) Sales of finished pharmaceutical products: The company generat...
CSPC Pharmaceutical Group Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
92
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.86B | 25.33B | 29.54B | 31.47B | 31.59B | 27.41B |
| Gross Profit | 22.17B | 16.62B | 20.67B | 22.19B | 22.73B | 20.79B |
| EBITDA | 9.99B | 5.24B | 7.16B | 8.59B | 8.83B | 7.58B |
| Net Income | 7.32B | 3.78B | 4.41B | 5.88B | 6.22B | 5.51B |
Balance Sheet | ||||||
| Total Assets | 56.01B | 46.72B | 44.36B | 46.28B | 41.18B | 34.68B |
| Cash, Cash Equivalents and Short-Term Investments | 18.48B | 8.87B | 7.75B | 13.09B | 13.87B | 10.73B |
| Total Debt | 652.37M | 641.38M | 507.33M | 706.90M | 582.54M | 93.87M |
| Total Liabilities | 16.59B | 12.15B | 10.52B | 11.26B | 10.06B | 7.91B |
| Stockholders Equity | 37.62B | 33.19B | 32.24B | 33.20B | 29.77B | 25.94B |
Cash Flow | ||||||
| Free Cash Flow | 12.21B | 3.99B | 1.74B | 2.29B | 6.62B | 2.88B |
| Operating Cash Flow | 13.78B | 5.90B | 4.26B | 4.18B | 8.10B | 4.64B |
| Investing Cash Flow | -8.65B | -4.13B | -4.41B | 607.27M | -7.19B | -637.33M |
| Financing Cash Flow | -2.21B | -2.44B | -5.11B | -2.30B | -1.95B | -2.20B |
CSPC Pharmaceutical Group Technical Analysis
Negative
9.52
Price Trends
8.99
Negative
8.37
Negative
8.49
Negative
Market Momentum
-0.28
Positive
34.40
Neutral
11.19
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1093, the sentiment is Negative. The current price of 9.52 is above the 20-day moving average (MA) of 8.84, above the 50-day MA of 8.99, and above the 200-day MA of 8.49, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 34.40 is Neutral, neither overbought nor oversold. The STOCH value of 11.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1093.
CSPC Pharmaceutical Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | HK$90.26B | 10.27 | 20.68% | 4.20% | 25.21% | 103.93% | |
68 Neutral | HK$29.12B | 6.18 | 7.92% | 5.17% | 7.94% | 52.83% | |
63 Neutral | HK$85.83B | 30.75 | 7.56% | 2.49% | 14.57% | -31.09% | |
63 Neutral | HK$64.52B | 11.88 | 6.64% | 5.88% | 9.12% | -3.22% | |
61 Neutral | HK$23.94B | 13.43 | 8.60% | 3.50% | 14.80% | -2.88% | |
57 Neutral | HK$35.32B | 14.74 | 5.57% | 6.71% | 6.00% | -23.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1093
CSPC Pharmaceutical Group
7.87
0.54
7.30%
HK:1177
Sino Biopharmaceutical
4.82
-2.08
-30.14%
HK:0867
China Medical System Holdings
9.82
-3.24
-24.82%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
12.86
-4.81
-27.23%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.11
0.04
0.41%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.64
-0.09
-1.86%
CSPC Pharmaceutical Group Corporate Events
CSPC launches Phase I/II trial for new B7‑H3 ADC in China
Oct 30, 2026
CSPC Pharmaceutical Group Limited, a Hong Kong–incorporated biopharmaceutical company, develops and markets innovative drugs, with a particular focus on oncology and other high‑value therapeutic areas. The group is building a pipeline ...
CSPC Launches Phase I Trial of mRNA Cancer Vaccine SYS6077 in China
Oct 28, 2026
CSPC Pharmaceutical Group has initiated a Phase I multi-centre clinical trial in China for SYS6077, an injectable Class 1 therapeutic biological product designed as a universal off-the-shelf mRNA cancer vaccine for advanced malignant tumours. The ...
CSPC Innovation Posts Strong Nine-Month Revenue and Profit Surge
Oct 28, 2026
CSPC Pharmaceutical Group announced that its subsidiary CSPC Innovation Pharmaceutical has released unaudited financial results for the nine months ended 30 September 2026, as required by the Shenzhen Stock Exchange. The report shows operating rev...
CSPC’s Novel Immuno-Oncology Drug Shows Early Promise in Advanced Solid Tumours
Oct 27, 2026
CSPC Pharmaceutical Group reported positive first-in-human Phase I/II data for SYS6090 (JMT108), an anti-PD-1/IL-15 bifunctional fusion protein, in patients with advanced solid tumours who had failed standard therapies. The results were highlighte...
CSPC’s B7-H3 ADC Shows Strong Phase I/II Results in Advanced Breast Cancer
Oct 27, 2026
CSPC Pharmaceutical Group has independently developed SYS6043, a B7-H3-targeted antibody-drug conjugate, as part of its expanding oncology pipeline focused on advanced solid tumours. The company is positioning itself as a key regional innovator in...
CSPC’s Anbenitamab Delivers Major Survival Gain in HER2-Positive Gastric Cancer Trial
Oct 26, 2026
CSPC Pharmaceutical Group reported updated overall survival results from its Phase III KC-WISE trial of Anbenitamab Injection (Ennituo) plus chemotherapy in HER2-positive advanced gastric and gastro-oesophageal junction adenocarcinoma patients who...
CSPC’s Anbenitamab Combo Delivers Superior Results in HER2-Positive Breast Cancer Trial
Oct 26, 2026
CSPC Pharmaceutical Group announced interim Phase III results from the HEALER study, showing its Anbenitamab injection, branded Ennituo, combined with albumin-bound docetaxel, significantly outperformed the long-standing THP regimen in first-line ...
CSPC Wins China Approval for First-in-Class Batoclimab Therapy in Myasthenia Gravis
Oct 23, 2026
CSPC Pharmaceutical Group announced that its in-licensed Batoclimab subcutaneous injection, marketed as Enlida, has received a drug registration certificate from China’s National Medical Products Administration for use with conventional ther...
CSPC Starts Phase II Trial of New RSV Drug SYH2066 in China
Oct 22, 2026
CSPC Pharmaceutical Group has officially begun a Phase II clinical trial in China for SYH2066, an orally administered small-molecule inhibitor targeting the fusion protein of respiratory syncytial virus. The candidate, classified as a Class 1 chem...
CSPC Launches Phase III Trial for Novel Triple-Negative Breast Cancer Drug in China
Oct 22, 2026
CSPC Pharmaceutical Group has initiated a Phase III clinical trial in China for SYS6043, a B7-H3-targeted antibody-drug conjugate designed as a first-line treatment for patients with unresectable recurrent or metastatic triple-negative breast canc...
CSPC Launches Phase I Trial of Dual-Target Dry Eye Drug SYH2083 in China
Oct 20, 2026
CSPC Pharmaceutical Group has initiated a Phase I clinical trial in China for SYH2083, an investigational eye drop developed to treat dry eye disease through a dual-target mechanism. The company is conducting the trial in healthy participants to a...
CSPC Pharma Grants 78 Million Restricted Shares Under 2026 Incentive Scheme
Oct 16, 2026
CSPC Pharmaceutical Group has granted 78,085,000 restricted shares, equal to about 0.678% of its issued share capital, to 205 employees under its 2026 Restricted Share Award Scheme. The shares, priced at HK$2.95 versus a market closing price of HK...
CSPC Wins China Trial Nod for Innovative Trispecific Cancer Antibody
Oct 15, 2026
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of SYS6088 Injection, a recombinant humanised trispecific antibody targeting PD-1, VEGFA and CTLA-4 in advanced or...
CSPC Grants 33.98 Million Restricted Shares Under Long-Term Incentive Plan
Oct 15, 2026
CSPC Pharmaceutical Group has granted 33,980,000 restricted shares, equal to about 0.29% of its issued share capital, to 260 employees under its 2018 Share Award Scheme at no purchase price. The shares will vest in five tranches between January 20...
CSPC Wins China Trial Nod for New Cancer Antibody-Drug Conjugate
Oct 15, 2026
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of SYS6062, a monoclonal antibody-drug conjugate targeting advanced solid tumours. The preclinical data showed ant...
CSPC Advances Nectin-4 ADC SYS6002 in Cervical Cancer After Positive Phase I Data
Oct 8, 2026
CSPC Pharmaceutical Group has reported Phase I data for SYS6002, a next-generation Nectin-4–targeting antibody-drug conjugate, used as a monotherapy in advanced cervical cancer and presented the results at the 2026 Annual Global Meeting of t...
CSPC to Showcase Breakthrough HER2 Oncology Data at ESMO 2026
Oct 5, 2026
CSPC Pharmaceutical Group will present data from eight oncology clinical trials at the ESMO Congress 2026 in Madrid, including two late-breaking abstracts spanning breast, lung, gastric, liver, colorectal, pancreatic cancers and rare tumours. The ...
CSPC’s Efmedaglutide Shows Strong Phase III Results Against Dulaglutide in Chinese Diabetes Trial
Sep 30, 2026
CSPC Pharmaceutical Group has reported positive Phase III trial results for its GLP-1 receptor agonist Efmedaglutide Alfa (TG103 Injection), used once weekly in combination with metformin in Chinese adults with type 2 diabetes mellitus. Presented ...
CSPC Wins U.S. FDA Nod for Clinical Trials of Recombinant Shingles Vaccine
Sep 29, 2026
CSPC Pharmaceutical Group has received U.S. Food and Drug Administration approval to begin clinical trials for its recombinant herpes zoster vaccine SYS6052, following earlier trial clearance in China. The vaccine targets adults aged 50 and above ...
CSPC Launches Phase Ib Trial of Obesity Biologic JMT206 in China
Sep 29, 2026
CSPC Pharmaceutical Group has initiated a Phase Ib clinical trial in China for JMT206, a recombinant fully human monoclonal antibody designed for weight management in adults with overweight or obesity. The drug targets activin receptor type IIA an...
CSPC Wins China Trial Nod for Novel mRNA Cancer Vaccine SYS6077
Sep 28, 2026
CSPC Pharmaceutical Group has received Chinese regulatory approval to begin clinical trials of SYS6077, an off‑the‑shelf therapeutic mRNA cancer vaccine designed for patients with advanced malignant tumours. The candidate uses the comp...
CSPC’s Becotatug Combo Hits Key Goal in Phase III EGFR ex20ins Lung Cancer Trial
Sep 24, 2026
CSPC Pharmaceutical Group reported that its Phase III trial of Becotatug (JMT101) combined with osimertinib for first-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations achieved its pr...
CSPC Launches Phase III Trial of Albumin-Bound Docetaxel for Advanced Breast Cancer in China
Sep 24, 2026
CSPC Pharmaceutical Group has officially initiated a Phase III clinical trial in China for HB1801, an albumin-bound docetaxel injection developed via its nanomedicine platform for treating advanced breast cancer. The company positions HB1801 as a ...
CSPC Advances Novel Dual-Target Diabetes Drug Into Phase II Trial in China
Sep 16, 2026
CSPC Pharmaceutical Group has officially launched a Phase II multicentre clinical trial in China for SYH2069 Injection, a novel long-acting dual GLP-1 and GIP receptor agonist for adult patients with type 2 diabetes mellitus. The therapy is engine...
CSPC’s ADC SYS6010 Wins Breakthrough Status in China for Hard-to-Treat Lung Cancer
Sep 15, 2026
CSPC Pharmaceutical Group announced that its antibody-drug conjugate SYS6010 has received Breakthrough Therapy Designation from China’s National Medical Products Administration for recurrent or metastatic actionable genomic alteration-negati...
CSPC Advances SYS6010 Lung Cancer Combo After Strong Phase I/II Data
Sep 14, 2026
CSPC Pharmaceutical Group reported Phase I/II trial data for SYS6010, an EGFR-targeting antibody-drug conjugate, combined with PD-1 inhibitor Enlonstobart in treatment-naive, advanced non-small cell lung cancer patients lacking actionable genomic ...
CSPC Wins China Trial Nod for First Ready-to-Use Goserelin Injection
Sep 9, 2026
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of its goserelin sustained-release injection, SYH9102, the world’s first ready-to-use formulation of this Gn...
CSPC Wins NMPA Nod for First Subcutaneous Long-Acting Rotigotine Parkinson’s Trial in China
Sep 9, 2026
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of its rotigotine long-acting injection SYH9087 for Parkinson’s disease. The once-weekly subcutaneous formul...
CSPC Wins China Trial Approval for Innovative SYH2083 Eye Drops
Sep 8, 2026
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials for SYH2083 eye drops, a Class 1 innovative small-molecule ophthalmic drug for dry eye disease. The therapy, which...
CSPC Launches Phase II Trial of Novel Influenza Drug in China
Sep 7, 2026
CSPC Pharmaceutical Group Limited, a Hong Kong-based pharmaceutical developer, is expanding its pipeline of innovative small-molecule drugs tailored to significant disease burdens in China. The company is increasingly focused on advancing Class 1 ...
CSPC’s SYS6010 Wins Third Breakthrough Therapy Tag in High-Need Cancer Indications
Sep 1, 2026
CSPC Pharmaceutical Group announced that its EGFR-targeting antibody-drug conjugate SYS6010 has received another Breakthrough Therapy Designation from China’s National Medical Products Administration for treating recurrent or metastatic head...
CSPC Launches Phase I Trial of Novel Depression Drug SYH2056 in China
Sep 1, 2026
CSPC Pharmaceutical Group has initiated a Phase I clinical trial in China for SYH2056, an investigational small-molecule 5-HT2A partial agonist tablet intended for the treatment of depression. The study will assess safety, tolerability, pharmacoki...
CSPC Launches First China Trial for New Obesity Drug SYH2092
Aug 31, 2026
CSPC Pharmaceutical Group has initiated a Phase I clinical trial in China for SYH2092, an injectable amylin receptor agonist developed for weight management in adults with overweight or obesity. The trial, launched after regulatory approval in Aug...
CSPC Advances Dual-Agonist Obesity Drug SYH2069 Into Phase II Trial in China
Aug 28, 2026
CSPC Pharmaceutical Group has initiated a Phase II clinical trial in China for SYH2069 Injection, a novel long-acting dual agonist targeting GLP-1 and GIP receptors for weight management in overweight and obese adults. The drug is designed to enha...
CSPC Wins China Trial Approval for Novel Obesity and Diabetes Drug
Aug 27, 2026
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of its SYH2092 injection, a highly potent amylin receptor agonist designed for weight management and glycaemic con...
CSPC Cancer Drug SYS6090 Wins U.S. FDA Fast Track Status
Aug 26, 2026
CSPC Pharmaceutical Group announced that its first-in-class PD-1/IL-15 bispecific fusion protein, SYS6090 (JMT108), has been granted Fast Track designation by the U.S. Food and Drug Administration for treating microsatellite-stable or proficient m...
CSPC’s EGFR-Targeting ADC Hits Phase III Milestone in Resistant Lung Cancer
Aug 26, 2026
CSPC Pharmaceutical Group reported that its investigational drug SYS6010, an EGFR-targeting antibody-drug conjugate, met the pre-specified primary endpoint of progression-free survival in a Phase III trial for EGFR-mutated locally advanced or meta...
CSPC Wins U.S. and China Approvals to Trial New RSV Vaccine in Seniors
Aug 25, 2026
CSPC Pharmaceutical Group has received approval from the U.S. Food and Drug Administration and China’s National Medical Products Administration to begin clinical trials for its recombinant respiratory syncytial virus vaccine SYS6057 in adult...
CSPC Pharmaceutical Profit More Than Doubles on Finished Drug Growth
Aug 20, 2026
CSPC Pharmaceutical Group reported strong interim results for the six months ended 30 June 2026, driven mainly by robust growth in its finished drugs segment. Group revenue rose 40.1% year-on-year to RMB18.59 billion, while reported profit attribu...
CSPC Pharmaceutical Declares Interim Dividend for First Half of 2026
Aug 20, 2026
CSPC Pharmaceutical Group Limited has declared an interim ordinary cash dividend of HKD 0.18 per share for the six months ended 30 June 2026, payable in Hong Kong dollars. The ex-dividend date is set for 20 October 2026, with the record date on 26...
CSPC Launches Phase Ib/II Trial of Novel PD-1/IL-15 Fusion Drug for Liver Cancer in China
Aug 19, 2026
CSPC Pharmaceutical Group has officially initiated a Phase Ib/II clinical trial of SYS6090 Injection, a Class 1 therapeutic biological product, at the first centre in China for the treatment of hepatocellular carcinoma. SYS6090 is a recombinant fu...
CSPC Seeks Priority Approval in China for Novel HER2-Positive Breast Cancer Regimen
Aug 18, 2026
CSPC Pharmaceutical Group announced that China’s National Medical Products Administration has accepted, under a priority review procedure, a new drug application for the combination of Anbenitamab (KN026) and its albumin-bound docetaxel (HB1...
CSPC Innovation Posts Strong Interim Turnaround With Tripled Revenue and Robust Profit
Aug 17, 2026
CSPC Pharmaceutical Group’s Shenzhen‑listed subsidiary, CSPC Innovation Pharmaceutical, released unaudited interim results for the six months ended 30 June 2026 showing a sharp turnaround to profitability. Revenue surged 208.72% year o...
CSPC Pharmaceutical Changes Trustee for 2018 Share Award Scheme
Aug 12, 2026
CSPC Pharmaceutical Group Limited has announced a change in the trustee for its 2018 Share Award Scheme, a restricted share-based incentive plan for selected participants. With effect from 12 August 2026, BOCI Trustee (Hong Kong) Limited will repl...
CSPC Receives US$30 Million Upfront Payment from AstraZeneca for siRNA Collaboration
Aug 12, 2026
CSPC Pharmaceutical Group has received an upfront payment of US$30 million from AstraZeneca under their recently signed collaboration, option and license agreement. The funding follows the July 2026 deal to jointly develop novel small nucleic acid...
CSPC Launches First-in-Class CAR-T Trial for Refractory Lupus in China
Aug 11, 2026
CSPC Pharmaceutical Group has initiated a Phase I clinical trial in China for SYS6063, a chimeric antigen receptor T-cell therapy designed to treat relapsed, refractory systemic lupus erythematosus. SYS6063 is described as the first CAR-T product ...
CSPC Pharmaceutical Sets Board Meeting to Approve Interim Results
Aug 10, 2026
CSPC Pharmaceutical Group Limited has scheduled a board meeting for 20 August 2026 to review and approve the unaudited interim results for the six months ended 30 June 2026. The announcement signals an upcoming disclosure of the company’s mi...
CSPC Wins U.S. FDA Nod for Clinical Trials of Novel Mpox mRNA Vaccine
Aug 10, 2026
CSPC Pharmaceutical Group has secured approval from the U.S. Food and Drug Administration to begin clinical trials of SYS6037, an mRNA-based mpox vaccine co-developed with the Institute of Microbiology of the Chinese Academy of Sciences. The vacci...
CSPC Pharmaceutical Group Secures US$10 Million Milestone From AstraZeneca
Aug 5, 2026
CSPC Pharmaceutical Group has received a US$10 million milestone payment from AstraZeneca under their strategic research collaboration, following AstraZeneca’s exercise of a license option for one of CSPC’s pre-clinical candidate progr...
CSPC and AstraZeneca Form Biologics Manufacturing Joint Venture in China
Aug 5, 2026
CSPC Pharmaceutical Group has signed a joint venture contract with AstraZeneca to build a new-generation biologics manufacturing facility in Shijiazhuang, China. CSPC will hold 51 percent and AstraZeneca 49 percent of the venture, which initially ...
CSPC Drug Combo for HER2-Positive Breast Cancer Wins Priority NMPA Review
Aug 4, 2026
CSPC Pharmaceutical Group announced that China’s National Medical Products Administration has accepted, under priority review, a new drug application for Anbenitamab (KN026) combined with its self-developed albumin-bound docetaxel (HB1801) f...
CSPC Launches Phase Ib/II Trial of Novel PD-1/IL-15 Fusion Therapy for Colorectal Cancer in China
Aug 3, 2026
CSPC Pharmaceutical Group has initiated a Phase Ib/II clinical trial in China for SYS 6090 Injection, a Class 1 therapeutic biological product designed as a recombinant fully human PD-1 and IL-15 fusion protein for colorectal cancer. The therapy a...
CSPC Wins China Trial Nod for New RSV Vaccine Targeting Seniors
Jul 31, 2026
CSPC Pharmaceutical Group announced that its recombinant respiratory syncytial virus vaccine, SYS6057, has received approval from China’s National Medical Products Administration to begin clinical trials. The vaccine uses an RSV prefusion F ...
CSPC Launches Phase II Trial of Novel Ovarian Cancer Therapy in China
Jul 31, 2026
CSPC Pharmaceutical Group has begun a Phase II clinical trial in China for SYS6041, an antibody-drug conjugate designed as a combination therapy for recurrent ovarian cancer. The drug targets folate receptor alpha, delivering a topoisomerase I inh...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.